Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Chromatin domains delimited by CTCF can restrict the range of enhancer action. However, disruption of some domain boundaries results in mild gene dysregulation and phenotypes. We tested whether perturbing a domain with multiple developmental regulators would lead to more severe outcomes. We chose a domain with three FGF ligand genes-Fgf3, Fgf4, and Fgf15-that control different murine developmental processes. Heterozygous deletion of a 23.9-kb boundary defined by four CTCF sites led to ectopic interactions of the FGF genes with enhancers active in the brain and induced FGF expression. This caused orofacial clefts, encephalocele, and fully penetrant perinatal lethality. Loss of the single CTCF motif oriented toward the enhancers-but not the three toward the FGF genes-recapitulated these phenotypes. Our works shows that small sequence variants at particular domain boundaries can have a surprisingly outsized effect and must be considered as potential sources of gene dysregulation in development and disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12237608PMC
http://dx.doi.org/10.1016/j.devcel.2025.02.002DOI Listing

Publication Analysis

Top Keywords

three fgf
12
single ctcf
8
ctcf motif
8
domain three
8
fgf genes
8
domain boundaries
8
gene dysregulation
8
domain
5
fgf
5
deletion single
4

Similar Publications

BackgroundWe explored the potential impact of testosterone treatment in a male rat model of chronic obstructive pulmonary disease (COPD). Our study focused on evaluating the potential decrease in the expression and activation of matrix metalloproteinase-9 (MMP-9) and fibroblast growth factor-23 (FGF-23) induced by COPD.MethodsWistar rats were randomly assigned to one of three groups: control, COPD, or testosterone treatment.

View Article and Find Full Text PDF

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome of abnormal phosphorus metabolism caused by increased secretion of fibroblast growth factor 23 (FGF23) by small mesenchymal tumors. In this article, we reported a patient with chronic refractory hypophosphatemia due to TIO who is treated with burosumab, a monoclonal antibody that targets and blocks the activity of FGF23. Treatment with burosumab led to the resolution of his refractory hypophosphatemia, but this was complicated by the development of secondary hyperparathyroidism.

View Article and Find Full Text PDF

Background: Human mesenchymal stem cells (MSCs) are a promising stem cell source; however, their therapeutic efficacy in chronic wound healing remains limited. This study evaluates the therapeutic potential of transforming growth factor (TGF)-β1-modified, three-dimensionally cultured MSCs (A/T-3D) for enhancing wound healing.

Methods: The TGF-β1 gene was inserted into a safe genomic locus in adipose-derived MSCs (ASCs) using transcription activator-like effector nucleases.

View Article and Find Full Text PDF

Background: Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies, with a rising global incidence. Despite advances in diagnosis and treatment, effective biomarkers for early detection and targeted therapy remain limited. β-Klotho (KLB), a co-receptor in the FGF signaling pathway, has been implicated in tumor progression and poor prognosis in several cancers.

View Article and Find Full Text PDF

Circulating FGF-21 as a Disease-Modifying Factor Associated with Distinct Symptoms and Cognitive Profiles in Myalgic Encephalomyelitis and Fibromyalgia.

Int J Mol Sci

August 2025

Viscogliosi Laboratory in Molecular Genetics of Musculoskeletal Diseases, Office 2.17.027, Azrieli Research Center, CHU Sainte-Justine, 3175 Cote-Ste-Catherine Road, Montreal, QC H3T 1C5, Canada.

Myalgic encephalomyelitis (ME) and fibromyalgia (FM) are overlapping syndromes characterized by persistent fatigue, cognitive difficulties, and post-exertional malaise (PEM), yet they lack objective biomarkers for diagnosis and treatment. Fibroblast growth factor 21 (FGF-21), a stress-responsive metabolic hormone, may offer a promising avenue to distinguish subtypes within these patient populations. In this cross-sectional study, plasma FGF-21 levels were measured in 250 patients (FM = 47; ME = 99; ME + FM = 104) and 54 healthy controls.

View Article and Find Full Text PDF